<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 8, 1997
KENSEY NASH CORPORATION
---------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-27120 36-3316412
- ---------------------------- ------------ ------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.
MARSH CREEK CORPORATE CENTER
55 EAST UWCHLAN AVENUE
SUITE 201
EXTON, PENNSYLVANIA 19341
----------------------------------------------------------------
(Address of Principal Executive Offices, including Zip Code)
Registrant's telephone number, including area code (610) 524-0188
<PAGE> 2
ITEM 5. OTHER EVENTS.
On November 13, 1997, the Registrant issued the news release attached as
Exhibit 99.1. The information contained in this news release is incorporated
herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 News Release of Registrant dated November 13, 1997.
99.2 Agreement dated November 10, 1997 by and among the
Registrant and Wouter M. Muijs Van de Moer, Rienk Rienks,
Innovasc R&D BV te Rotterdam and Medifix R&D BV te Putten.
ITEM 9. SALES OF EQUITY SECURITIES PURSUANT TO REGULATION S.
On December 8, 1997, pursuant to the attached Agreement (the "Agreement"), the
Registrant issued a total of 200,000 shares of its common stock, par value
$0.001 per share (the "Shares"), to Innovasc R&D BV te Rotterdam ("Innovasc")
and Medifix R&D BV te Putten ("Medifix"), in exchange for certain patent rights
held by Innovasc and Medifix. The Shares were issued outside the United States
in reliance on Regulation S of the Securities Act of 1933, as amended (the
"Act"). No underwriters or other distributors were involved in the
transaction. Innovasc and Medifix represented that they were not U.S. persons
and that they would not sell the Shares to U.S. persons or in the United States
without complying with the registration requirements of the 1933 Act or relying
on an exemption therefrom. The offer and sale of the Shares occurred in The
Netherlands in an "offshore transaction", and neither the Registrant nor any of
its affiliates engaged in any "directed selling efforts" in the United States
(as those terms are defined under Regulation S). Innovasc and Medifix
represented to the foregoing in the Agreement.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KENSEY NASH CORPORATION
Dated: December 8, 1997 By: /s/ JOSEPH W. KAUFMANN
------------------------
Joseph W. Kaufmann
Chief Executive Officer,
President and
Chief Financial Officer
<PAGE> 4
Exhibit Index
<TABLE>
<CAPTION>
Exhibit # Item
- ------------- -------------
<S> <C>
99.1 News Release
99.2 Agreement
</TABLE>
<PAGE> 1
FOR IMMEDIATE RELEASE
- ---------------------
CONTACT:
Joseph W. Kaufmann Cindy Glynn (investor)
President and Chief Executive Officer Susan Farley (media)
(610) 524-0188 Dewe Rogerson
(212) 688-6840
KENSEY NASH ACQUIRES PATENTS RELATED TO
PUNCTURE CLOSURE TECHNOLOGY
-ROYALTY RATES PAID TO KENSEY NASH WILL INCREASE-
EXTON, PA, November 13, 1997 -- Kensey Nash Corporation (Nasdaq: KNSY) today
announced that it has acquired a portfolio of puncture closure patents and
patent applications, which will result in a 33 to 50% increase in the royalties
paid to the Company for the Angio-Seal product by Sherwood-Davis & Geck, a
subsidiary of American Home Products Corporation (AHP:NYSE).
The intellectual property was acquired from two doctors, who had licensed their
inventions to AHP in 1995. The licenses were subsequently transferred to
Sherwood-Davis & Geck, who holds a worldwide exclusive license to the acquired
patents and will continue to do so. As a result of acquiring the patents,
Kensey Nash will be entitled to earn the royalty fees formerly paid by
Sherwood-Davis & Geck to the doctors for each Angio-Seal device sold,
commencing in 1998.
Under the terms of the agreement, Kensey Nash will pay a combination of Common
Stock and cash payments for the transfer of ownership of the patents.
Separately, Drs. Wouter M.M. Van de Moer and Rienk Rienks, inventors of the
acquired intellectual property, have agreed to join Kensey Nash's Medical
Advisory Board.
"Based on our projections, we believe that this addition to our worldwide
patent portfolio will have a substantial impact on our bottom line," stated
Joseph W. Kaufmann, president and CEO of Kensey Nash Corporation. "We look
forward to a long and mutually rewarding relationship with these creative and
experienced cardiologists."
"We are pleased to be a part of the growing success of not only the Angio-Seal
product, but the many innovative and exciting technologies that Kensey Nash is
developing," commented Drs. Van de Moer and Rienk Rienks. "We look forward to
continued involvement in Kensey Nash through stock ownership and active
participation on Kensey Nash's Medical Advisory Board."
Kensey Nash is a medical device company focused on the commercialization and
continuing development of a line of absorbable medical devices for the sealing
of arterial punctures created during cardiovascular procedures. Kensey Nash's
principal product, the Angio-Seal device, provides a safe, effective and quick
method of sealing arterial punctures and is designed to lower procedure costs
and enhance patient comfort. The 8F Angio-Seal device, the Company's primary
product, received FDA pre-market approval on September 30, 1996. The device is
being marketed worldwide by Sherwood-Davis & Geck, a subsidiary of AHP.
Statements contained in this press release that are not historical facts are
forward-looking statements that are made pursuant to the Safe Harbor provisions
of the Private Securities Litigation Reform Act of 1995. The Company cautions
that a number of important factors could cause the Company's actual results to
differ materially from those in the forward-looking statements including,
without limitation, AHP's ability to successfully manufacture and market the
Angio-Seal device, additional regulatory approvals, the Company's ability to
manufacture Angio-Seal components and competition from other puncture closure
devices. Results of operations in any past period should not be considered
indicative of the results to be expected for future periods. Fluctuations in
operating results may also result in fluctuations in the price of the Common
Stock.
<PAGE> 1
AGREEMENT
THIS AGREEMENT made this tenth day of November, 1997 by and among KENSEY
NASH CORPORATION, a corporation organized and existing under the laws of the
State of Delaware, having offices at 55 East Uwchlan Avenue, Exton, PA 19341
(hereinafter referred to as "KENSEY NASH") and Wouter M. Muijs Van de Moer
(hereinafter referred to as "VAN DE MOER") and Rienk Rienks (hereinafter
referred to as "RIENKS"), both citizens of the Netherlands and residing at
Grindweg 56, 3055 VB Rotterdam, Netherlands and Mennestraat 17, 3882 AN Putten,
Netherlands, respectively, and INNOVASC R&D BV te Rotterdam (hereinafter
referred to as "INNOVASC") and MEDIFIX R&D BV te Putten (hereinafter referred
to as "MEDIFIX").
WITNESSETH:
WHEREAS, KENSEY NASH is involved in the business of developing and
manufacturing medical and/or surgical apparatus, systems, procedures, devices,
and components and has made numerous inventions in this field and is the owner
of various intellectual property relating thereto;
WHEREAS, VAN DE MOER and RIENKS have made inventions relating to the
sealing of openings in blood vessels and are the owners of various patent
applications and patents relating thereto as set forth in Exhibit A hereunto
attached;
WHEREAS, VAN DE MOER and RIENKS have granted licenses to American Home
Products Corporation, pursuant to two License Agreements each dated February 8,
1995 (the "License Agreements"), relating to the patent applications and
patents as set forth in Exhibit A;
WHEREAS, VAN DE MOER on or about August 11, 1995 contributed and
transferred to INNOVASC all of his right, title and interest in and to the
Patent Property (as hereinafter defined) a copy of said assignment and transfer
is attached hereto as Exhibit B, and RIENKS on or about August 11, 1995
contributed and transferred to MEDIFIX all of his right, title and interest in
and to the Patent Property, a copy of said assignment and transfer is attached
hereto as Exhibit C;
WHEREAS, INNOVASC and MEDIFIX are in the process of filing all required
notices of said assignments and transfers but have not made or completed all
such filings as of the date of this Agreement;
WHEREAS, KENSEY NASH in the furtherance of its business desires to acquire
(i) all right, title, and interest in and to all of said inventions, patent
applications and issued
1
<PAGE> 2
patents of INNOVASC AND MEDIFIX listed in Exhibit A and any patent
application(s) and/or patent(s) based or issuing thereon, including but not
limited to reissues, renewals, divisionals and continuing applications,
throughout the world and (ii) the rights of VAN DE MOER, RIENKS, INNOVASC AND
MEDIFIX pursuant to the License Agreements (all of the foregoing being
hereinafter collectively referred to as "Patent Property");
WHEREAS, INNOVASC AND MEDIFIX are desirous of transferring all of their
respective right, title, and interest in and to said Patent Property to KENSEY
NASH in return for certain consideration hereinafter set forth; and
WHEREAS, KENSEY NASH on one hand and VAN DE MOER, RIENKS, INNOVASC AND
MEDIFIX, on the other hand are desirous of entering into this Agreement to
effectuate the foregoing upon the terms and conditions set forth hereinafter.
NOW THEREFORE, in consideration of the foregoing premises and the
consideration and mutual covenants contained herein, the sufficiency of which
is hereby acknowledged, and intending to be legally bound hereby, KENSEY NASH
on one hand and VAN DE MOER, RIENKS, INNOVASC AND MEDIFIX on the other hand
hereby mutually promise and agree as follows:
1. Transfer of Patent Property.
(a) Subject to compliance with all of the terms and conditions of this
Agreement and in reliance on the representations and warranties set forth in
this Agreement, INNOVASC AND MEDIFIX hereby sell, assign and transfer all
right, title, and interest in and to the Patent Property to KENSEY NASH, as
well as all rights to sue and collect for past infringement thereof, free and
clear of any and all encumbrances. Notwithstanding the transfer of the Patent
Property to KENSEY NASH, INNOVASC AND MEDIFIX shall be entitled to receive all
royalty payments payable and owing pursuant to the License Agreements until
December 31, 1997.
(b) INNOVASC AND MEDIFIX each agree to execute the Assignment attached
hereto as Exhibit D contemporaneously with the signing of this Agreement so
that said Assignment may be recorded, as desired, by KENSEY NASH.
(c) VAN DE MOER, RIENKS, INNOVASC AND MEDIFIX further agree that each
shall execute and, if necessary, acknowledge and deliver any and all
agreements, instruments, documents and papers and take all such further action
that may be necessary or desirable to carry out and effectuate the purposes and
intent of this Agreement, including, but not limited to executing any further
assignments and any releases and applications for reissues, renewals,
divisionals, continuing applications and/or patents issued thereon that may be
deemed necessary by KENSEY NASH fully to secure to KENSEY NASH its interest in
and to the Patent Property.
2
<PAGE> 3
(d) In the event that any proceedings are at any time instituted by way of
claim, petition, or counterclaim impugning the validity of any patent or patent
application of the Patent Property vested in KENSEY NASH pursuant to this
Agreement VAN DE MOER, RIENKS, INNOVASC AND MEDIFIX agree to render all
reasonable assistance to KENSEY NASH in relation thereto. VAN DE MOER, RIENKS,
INNOVASC and MEDIFIX shall be reimbursed for all costs and expenses reasonably
incurred by them, respectively, in complying with the requirements of this
subsection.
2. Representations.
(a) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that INNOVASC and MEDIFIX are corporations duly
incorporated, validly existing and in good standing under the laws of The
Netherlands and each has the requisite corporate power to own its property and
to carry on its business as presently conducted.
(b) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that the execution, delivery and performance of this
Agreement by INNOVASC and MEDIFIX has been duly and validly authorized by the
Board of Directors of INNOVASC and MEDIFIX, and this Agreement has been duly
and validly executed and delivered by VAN DE MOER, RIENKS, INNOVASC and MEDIFIX
and constitutes the valid and binding agreement of VAN DE MOER, RIENKS,
INNOVASC and MEDIFIX, enforceable in accordance with its terms, subject to
bankruptcy, reorganization, insolvency, fraudulent conveyance, moratorium,
receivership or other similar laws relating to or affecting creditors' rights
generally.
(c) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that INNOVASC and MEDIFIX have all requisite corporate
power and authority to execute, deliver and perform this Agreement and to carry
out the transactions contemplated hereby.
(d) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that neither the execution of this Agreement by VAN DE
MOER, RIENKS, INNOVASC and MEDIFIX, nor the consummation by VAN DE MOER,
RIENKS, INNOVASC and MEDIFIX of the transactions contemplated hereby, will
constitute a violation of, or be in conflict with, or constitute or create a
default under any agreement or arrangement binding upon VAN DE MOER, RIENKS,
INNOVASC or MEDIFIX, or result in the creation of any mortgage, lien, pledge,
charge, security interest or any encumbrance of any nature whatsoever on any
asset of VAN DE MOER, RIENKS, INNOVASC or MEDIFIX, or conflict
3
<PAGE> 4
with or violate any provision of the corporate formation documents of INNOVASC
or MEDIFIX.
(e) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that no statutory or regulatory rule or order of a court
or a governmental body applicable to VAN DE MOER, RIENKS, INNOVASC or MEDIFIX,
and no agreement between VAN DE MOER, RIENKS, INNOVASC or MEDIFIX and any such
governmental body is in effect which restrains or prohibits the sale and
assignment by INNOVASC and MEDIFIX of the Patent Property as reflected in this
Agreement, nor the consummation of any of the other transactions contemplated
hereby, nor is there pending or (to the best of VAN DE MOER, RIENKS, INNOVASC
or MEDIFIX's knowledge, information and belief) threatened any action, suit,
proceeding or investigation by any person, entity or governmental body which
questions or might jeopardize the validity of this Agreement or challenges any
of the transactions contemplated hereby.
(f) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that except as set forth in this Agreement, no consent,
approval, or authorization of or registration, designation, declaration or,
except for filings necessary to consummate the transactions contemplated by
this Agreement or the transfer of the Patent Property by VAN DE MOER and RIENKS
to INNOVASC and MEDIFIX, respectively, filing with any governmental authority
on the part of VAN DE MOER, RIENKS, INNOVASC or MEDIFIX is required in
connection with the sale and assignment of the Patent Property pursuant to this
Agreement or the consummation of any other transactions contemplated hereby.
(g) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that no finder's fee or brokerage fee is payable to any
person by VAN DE MOER, RIENKS, INNOVASC or MEDIFIX as a result of any action by
VAN DE MOER, RIENKS, INNOVASC or MEDIFIX in connection with the transactions
contemplated by this Agreement.
(h) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that the inventory of patent applications and patents set
forth in Exhibit A is complete and that no other patent application and/or
patent of VAN DE MOER, RIENKS, INNOVASC and/or MEDIFIX relating to the subject
matter of this Agreement exists, and to the extent that any does, such patent
application(s) and/or patent(s) is(are) included in the Patent Property sold,
assigned and transferred to KENSEY NASH by this Agreement.
(i) VAN DE MOER and RIENKS jointly and severally warrant and represent
that as of the date of their respective contributions to INNOVASC and MEDIFIX,
each had the authority to transfer and convey their respective right, title,
and interest in and to the Patent Property to
4
<PAGE> 5
INNOVASC and MEDIFIX, respectively, and that prior to said transfer neither had
encumbered any right, title or interest in or to the Patent Property.
(j) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that both INNOVASC and MEDIFIX have the full right to
convey the entire right, title, and interest herein sold, assigned and
transferred, that each has not encumbered any right, title, and interest in and
to the Patent Property and that each has not executed, and will not execute,
any agreements in conflict herewith nor do (or omit to be done) any act,
matter, or thing whereby any of the Patent Property may be invalidated.
(k) INNOVASC and MEDIFIX jointly and severally warrant and represent that
the only license(s) granted by either of them with respect to the Patent
Property are the aforesaid License Agreements and which are included in the
Patent Property.
(l) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they have received a copy of KENSEY NASH's Annual
Report on Form 10-K for the year ended June 30, 1997 and Proxy Statement for
its Annual Meeting to be held on December 3, 1997 (the "Information").
(m) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they have received no representations, warranties or
written communications with respect to the offering of the Shares (as
hereinafter defined) other than those contained in the Information and the
Agreement and VAN DE MOER, RIENKS, INNOVASC and MEDIFIX are not relying upon
any information other than that (i) contained in the Information or the
Agreement, or (ii) resulting from VAN DE MOER, RIENKS, INNOVASC and MEDIFIX's
own investigation of KENSEY NASH.
(n) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they are not relying on KENSEY NASH for investment
advice. VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally warrant
and represent that they have carefully considered and have, to the extent VAN
DE MOER, RIENKS, INNOVASC and MEDIFIX believe such discussion necessary,
discussed with their professional legal, tax, accounting and financial advisers
the suitability of an investment in the Shares for their particular tax and
financial situation.
(o) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they have had an opportunity to request and obtain
any additional information VAN DE MOER, RIENKS, INNOVASC and MEDIFIX deemed
necessary to verify the information contained in the Information.
5
<PAGE> 6
(p) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that (i) each of them is not a "U.S. person" as that
term is defined in Rule 902 under the Securities Act of 1933, as amended (the
"Act"), (ii) they are not acquiring the Shares for the account or benefit of a
U.S. person and (iii) for a period of forty (40) days (or any longer period
required by applicable law or regulation under the Act that may become
effective and be applicable to the Shares prior to the issuance thereof), they
shall not engage in any activity for the purpose of, or which may reasonably be
expected to have the effect of, conditioning the market in the United States
for the Shares or offer or sell such Shares in the United States or, except as
hereinafter provided, to, or for the account or benefit of a U.S. person.
(q) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they are executing this Agreement outside the United
States.
(r) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that the Shares were not offered to them in the United
States nor by means of any "directed selling efforts" as that term is defined
in Rule 902 under the Act.
(s) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they understand that the Shares have not been
registered under the Act, nor under the securities laws of any state or other
jurisdiction. VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they understand that: (i) the offering and sale of
the Shares is intended to be exempt from registration under the Act by virtue
of Regulation S of the Act (and the rules and regulations promulgated
thereunder) and applicable state securities laws, and (ii) the Shares have not
been approved or disapproved by the United States Securities and Exchange
Commission (the "Commission") or by any other federal or state agency, and no
such agency has passed on the accuracy or adequacy of the Information, nor made
any finding or determination as to the fairness or suitability of an investment
in the Shares.
(t) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they understand that there are restrictions on the
transferability of the Shares as stated in the Agreement which restrict
INNOVASC and MEDIFIX's ability to liquidate their respective investment in any
of the Shares. VAN DE MOER, RIENKS, INNOVASC and MEDIFIX severally, but not
jointly, warrant and represent that all subsequent offers and sales of the
Shares shall be made in compliance with Regulation S, pursuant to registration
of the Shares under the Act, or pursuant to an available exemption from the
registration requirements of the Act.
6
<PAGE> 7
(u) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they understand and acknowledge that KENSEY NASH is
relying upon the representations and warranties contained in this Agreement in
determining whether the offering is eligible for exemption from the
registration requirements contained in the Act and applicable state securities
law.
(v) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
warrant and represent that they agree that the representations, warranties,
acknowledgments and agreements made by them herein shall survive the Closing.
(w) KENSEY NASH warrants and represents that
(i) KENSEY NASH is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of
Delaware and has the corporate power to own its property and
to carry on its business as presently conducted;
(ii) the execution, delivery and performance of this Agreement by
KENSEY NASH has been duly and validly authorized by the Board
of Directors of KENSEY NASH, and this Agreement has been duly
and validly executed and delivered by KENSEY NASH and
constitutes the valid and binding agreement of KENSEY NASH,
enforceable in accordance with its terms, subject to
bankruptcy, reorganization, insolvency, fraudulent conveyance,
moratorium, receivership or other similar laws relating to or
affecting creditors' rights generally;
(iii) KENSEY NASH has all requisite corporate power and authority
to execute, deliver and perform this Agreement and to carry
out the transactions contemplated hereby;
(iv) neither the execution of this Agreement by KENSEY NASH nor
the consummation by KENSEY NASH of the transactions
contemplated hereby will constitute a violation of, or be in
conflict with, or constitute or create a default under any
agreement or arrangement binding upon KENSEY NASH, or result
in the creation of any mortgage, lien, pledge, charge,
security interest or any encumbrance of any nature whatsoever
on
7
<PAGE> 8
any asset of KENSEY NASH, or conflict with or violate any
provision of the Certificate of Incorporation or By-laws of
KENSEY NASH;
(v) no statutory or regulatory rule or order of a court or a
governmental body applicable to KENSEY NASH, and no
agreement between KENSEY NASH and any such governmental body
is in effect which restrains or prohibits the acquisition by
KENSEY NASH of the Patent Property as reflected in this
Agreement nor the consummation of any of the other
transactions contemplated hereby nor is there pending or (to
the best of KENSEY NASH's knowledge, information and belief)
threatened any action, suit, proceeding or investigation by
any person, entity or governmental body which questions or
might jeopardize the validity of this Agreement or
challenges any of the transactions contemplated hereby;
(vi) except as set forth in this Agreement, no consent, approval,
or authorization of or registration, designation,
declaration or filing with any governmental authority on the
part of KENSEY NASH is required in connection with the
acquisition of the Patent Property pursuant to this
Agreement or the consummation of any other transactions
contemplated hereby;
(vii) no finder's fee or brokerage fee is payable to any person by
KENSEY NASH as a result of any action by KENSEY NASH in
connection with the transactions contemplated by this
Agreement;
(viii) the Shares, when issued in accordance with the terms of this
Agreement, will have been duly and validly authorized and
issued, will be fully paid and non assessable and will not
have been issued in violation of the preemptive rights of any
person; and
(ix) KENSEY NASH has filed with the Commission all material
forms, statements, reports and documents required to be
filed by it under each of the Act, the Securities Exchange
Act of 1934 (the "1934 Act"), and their respective rules and
regulations, all of which, as amended, if applicable,
complied when filed in all material respects with all
applicable requirements of the appropriate such Act and the
rules and regulations thereunder. The Annual Report on Form
10-K of KENSEY NASH for the fiscal year ended June 30, 1997
filed with the Commission under the 1934 Act, and all other
reports and proxy statements filed or required to be filed
by KENSEY NASH under the 1934 Act, since June 30, 1997 and
for the
8
<PAGE> 9
twelve month period prior to the date of this Agreement,
have been duly and timely filed were in substantial
compliance with the requirements of their respective forms
and applicable rules and regulations and were complete and
correct in all material respects as of the dates at which
the information was furnished, and contained no untrue
statement of a material fact and did not omit to state any
material fact required to be included therein or necessary
to make the statements therein, in light of the
circumstances under which the statements made therein were
made, not misleading. No event has occurred which would be
required to be reported by KENSEY NASH in a Current Report
on Form 8-K which has not been so reported thereon.
(x) KENSEY NASH warrants and represents that the Shares shall have been
approved for listing on The Nasdaq National Market.
(y) KENSEY NASH warrants, represents and agrees that it will do and take
all actions reasonably necessary or desirable to maintain, protect and preserve
the Patent Property in accordance with the standards it currently employs to
protect its patent property and will not sell or otherwise dispose of the
Patent Property, except in connection with a sale of all or substantially all
of the assets or stock of KENSEY NASH, or permit the Patent Property to become
subject to any lien, charge or encumbrance until all Cash Payments (as
hereinafter defined) have been made.
(z) KENSEY NASH warrants and represents that it agrees that the
representations, warranties, acknowledgments and agreements made by it herein
shall survive the Closing.
3. Payments; Closing.
(a) Subject to compliance with all the terms and conditions of this
Agreement and in reliance on the representations and warranties set forth in
this Agreement, in partial consideration for the sale, assignment and transfer
of the Patent Property, KENSEY NASH agrees to issue to INNOVASC and MEDIFIX
200,000 shares of authorized but unissued shares of Common Stock of KENSEY NASH
(the "Shares"), provided, however that (i) if the last quoted sales price on
the Nasdaq Stock Market of the Common Stock of KENSEY NASH on the day this
Agreement is executed (the "Last Sales Price") is greater than $15.00 per
share, the number of Shares to be issued by KENSEY NASH to INNOVASC and MEDIFIX
shall be reduced so as to equal the quotient of $3,000,000 divided by the Last
Sales Price, and (ii) if the Last Sales Price is less than $14.00 per share,
the number of Shares to be issued by KENSEY NASH to INNOVASC and
9
<PAGE> 10
MEDIFIX shall be increased so as to equal the quotient of $2,800,000 divided
by the Last Sales Price.
(b) In partial consideration for the sale, assignment and transfer of the
Patent Property on each of March 31, 1998, June 30, 1998, September 30, 1998
and December 31, 1998, KENSEY NASH shall transfer to INNOVASC and MEDIFIX, an
aggregate of $125,000 in United States Dollars in immediately available funds.
On each of March 31, 1999, June 30, 1999, September 30, 1999 and December 31,
1999, KENSEY NASH shall transfer to INNOVASC and MEDIFIX, an aggregate of
$175,000 in United States Dollars in immediately available funds. The cash
payments under this subsection are collectively referred to as the "Cash
Payments."
(c) The Closing of the sale, assignment and transfer by INNOVASC and
MEDIFIX to KENSEY NASH of the Patent Property and delivery of the Shares by
KENSEY NASH TO INNOVASC AND MEDIFIX in partial consideration therefor shall
take place in Amsterdam, The Netherlands, on or about December 8, 1997, at such
place and time as the parties hereto shall agree. At the Closing, the
Assignment shall be delivered to KENSEY NASH by INNOVASC and MEDIFIX and the
Shares shall be delivered to INNOVASC and MEDIFIX.
(d) The Shares and Cash Payments are to be made and/or delivered in equal
amounts to INNOVASC and MEDIFIX, one half to each of them.
4. Governing Law; Arbitration and Venue.
(a) This Agreement shall be governed by, interpreted, construed and
enforced in accordance with the laws of the Commonwealth of Pennsylvania.
(b) Any controversy or claim arising out of or relating to this Agreement,
or any breach thereof, shall be settled by decision of a panel of three (3)
neutral arbitrators to be selected pursuant to the Commercial Arbitration Rules
of the American Arbitration Association. The venue of any such arbitration
shall be in New York, New York, U.S.A., and the arbitration shall be conducted
pursuant to the rules of said Association.
5. Captions and Exhibits. Captions in this Agreement are solely for purposes
of identification and shall not in any manner alter or vary the interpretation
of construction of this Agreement. All Exhibits which are, or may be,
attached to this Agreement are to be considered to be incorporated herein by
reference as if set forth at length.
6. Integration. It is the desire and intent of the parties to provide
certainty as to their future rights and undertakings herein. The parties in
this Agreement have incorporated all representations,
10
<PAGE> 11
warranties, covenants, commitments and understandings on which they have relied
in entering into this Agreement, and, neither party makes any covenant or other
commitment to the other concerning its future action. Accordingly, this
Agreement (i) constitutes the entire Agreement and understanding between the
parties and there are no promises, representations, conditions, provisions or
terms related thereto other than those forth in this Agreement, and (ii)
supersedes all previous undertakings, agreements and representation between the
parties, written or oral, with respect to the subject matter hereof. No
modification of, addition to, or waiver of any provisions of this Agreement
shall be binding upon either party hereto unless the same shall be in writing
duly executed by a duly authorized representative of both parties hereto.
7. Severability. Wherever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement shall be prohibited by or invalid under
applicable law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Agreement.
8. Waiver. No express or implied waiver by either party of any right or remedy
with respect to a default by the other party under any provision of this
Agreement shall be deemed, interpreted or construed as a waiver of any right or
remedy with respect to any other default under the same or any other provision
hereof.
9. Successors and Assigns. All the terms and provisions of this Agreement
shall be binding upon and shall inure to the benefit of the parties hereto and
their heirs, personal representatives, transferees, successors and assigns.
10. Non-Disclosure. Except as otherwise provided herein, each party warrants
and represents that it has not, and covenants and agrees that it will not, for
a period of two years after the date of this Agreement, disclose to any other
party, orally or in writing, formally or informally, any of the terms and
conditions of this Agreement and the transactions contemplated hereby.
(a) Formal announcements by either party hereto of the transactions
contemplated hereby must be approved in advance by the other party, which
approval will not unreasonably be withheld.
(b) No provision of this Section shall be construed as prohibiting the
following disclosures: (i) disclosures of such information as may be required
for federal securities, tax, accounting or other reporting purposes, (ii)
disclosures to immediate family members, legal counsel, independent accountants
and other representatives, (iii) disclosures pursuant to the terms of an order
of a court or other governmental authority of competent jurisdiction, or (vi)
11
<PAGE> 12
disclosures required in connection with legal proceedings or disclosures of
matters of which there is public knowledge other than as a result of
disclosures made in breach hereof.
11. Resale Restrictions: Legend and Lock-up.
(a) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX severally, but not jointly,
acknowledge and agree that after the Closing: (i) the Shares may not be sold,
assigned or otherwise transferred unless a registration statement is in effect
with respect to such resale or an exemption for such resale under applicable
securities law registration requirements exists with respect to such sale (as
evidenced by an opinion of counsel delivered and addressed to KENSEY NASH,
which opinion must be reasonably acceptable to KENSEY NASH), (ii) KENSEY NASH
is under no obligation to prepare or file a registration statement for the
Shares at any time, (iii) the certificates evidencing the Shares will bear the
following legends in substantially the following form:
"The shares represented by this certificate have not been registered
under the Securities Act of 1933, as amended (the "Act"), or under any
state securities laws, and thus may not be sold, assigned or otherwise
transferred unless so registered or unless an exemption from registration
is available, which exemption shall be established by an opinion of
counsel, reasonably satisfactory in form and substance to the issuer and
delivered and addressed to the issuer by counsel for the registered owner
of the shares evidenced hereby" and
"Until 40 days or such longer period that may be required under
applicable law or regulation under the Act, the shares represented by
this certificate may not be sold to a U.S. person or into the United
States."
; and (iv) KENSEY NASH will issue instructions to its transfer agent to
the effect that subsequent transfer of the Shares may not be effected unless
the transfer agent has received evidence reasonably satisfactory to it that
such transfer may be made without violating applicable securities laws.
(b) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX severally, but not jointly,
covenant and agree, with respect to the number of Shares and periods of time
listed on Schedule 1 hereto, not to (i) offer, pledge, sell, contract to sell,
sell any option or contract to purchase or purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any of the Shares during any period of time
specified, in excess of the number of Shares set forth on Schedule 1 for such
period; provided that if the permitted number of Shares is not sold or
otherwise disposed of during any such time period the Shares not sold or
otherwise disposed of shall be carried forward
12
<PAGE> 13
and added to the number of Shares which may be sold or otherwise disposed of
during the next succeeding time period, and this procedure shall be repeated in
subsequent time periods; or (ii) enter into any swap or other arrangements that
transfer all or a portion of the economic consequences associated with the
ownership of the Shares (regardless of whether any of the transactions
described in clause (i) or (ii) is to be settled by the delivery of Common
Stock or other securities of KENSEY NASH, in cash or otherwise), without the
prior written consent of KENSEY NASH. VAN DE MOER, RIENKS, INNOVASC and MEDIFIX
jointly and severally authorize KENSEY NASH to cause the transfer agent to
decline to transfer and/or to note stop transfer restrictions on the transfer
books and records of KENSEY NASH with respect to any of the Shares for which
INNOVASC and MEDIFIX is the record holder and, in the case of any such Shares
for which INNOVASC and MEDIFIX is the beneficial but not the record holder,
agree to cause the record holder to cause the transfer agent to decline to
transfer and/or to note stop transfer restrictions on such books and records
with respect to such Shares.
12. Non-Competition.
(a) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX severally, but not
jointly, covenant and agree that none of them nor any of their affiliates,
successors or assigns will, for a period of three (3) years from the Closing
Date, without KENSEY NASH's prior written consent, by itself or in partnership
or conjunction with, or as a manager, consultant or agent of, any other person,
firm, corporation or other entity, either directly or indirectly, undertake or
carry on or be engaged or have any financial or other interest in, or in any
other manner advise or assist, any person, firm, corporation or other entity
engaged or interested in, any business (any such business is referred to herein
as a "Competitive Business") involving the Patent Property or other vascular
closure devices on a worldwide basis. The ownership of an equity interest of
five percent (5%) or less of any publicly-traded entity shall not be deemed a
violation of this covenant.
(b) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally agree
and warrant that the covenants contained in this Section are reasonable, that
valid consideration has been received therefor and that the agreements set
forth in this Section are the result of arm's-length negotiation between the
parties hereto.
(c) VAN DE MOER, RIENKS, INNOVASC and MEDIFIX jointly and severally
acknowledge that in the event of any violation of the covenants contained in
this Section 12 or Section 10, KENSEY NASH's damages will be difficult to
ascertain and KENSEY NASH's remedy at law may be inadequate. Accordingly, VAN
DE MOER and RIENKS severally, but not jointly, agree that in the event of any
violation, (i) they shall forfeit the Cash Payments, (ii) they shall forfeit to
KENSEY NASH any and all consideration or profit (in whatever form) received or
to be received in connection with such violation and (iii) KENSEY NASH shall
be
13
<PAGE> 14
entitled to specific performance of such covenants and to an injunction to
prevent any continuing violation thereof without the necessity of posting a
bond.
(d) If any of the provisions of or covenants contained in this Section is
hereafter construed to be invalid or unenforceable in any jurisdiction, the
same shall not affect the remainder of the provisions or the enforceability
thereof in any other jurisdiction, which shall be given full effect, without
regard to the invalidity or unenforceability in such other jurisdiction. If
any of the provisions of or covenants contained in this Section is held to be
unenforceable in any jurisdiction because of the duration or geographical scope
thereof, the parties agree that the court making such determination shall have
the power to reduce the duration or geographical scope of such provision or
covenant and, in its reduced form, said provision or covenant shall be
enforceable; provided, however, that the determination of such court shall not
affect the enforceability of this Section in any other jurisdiction.
13. Default. In the event KENSEY NASH fails to make, when due, any of the
Cash Payments referred to in Section 3 of this Agreement within thirty (30)
days after the date such Cash Payment becomes due and payable thereunder and is
notified in writing of that failure by certified mail, return receipt
requested, attention Joseph W. Kaufmann, President, Kensey Nash Corporation,
KENSEY NASH shall have fourteen (14) days from the date of such notification to
cure said failure, and if said failure is not cured within said fourteen (14)
days, KENSEY NASH hereby agrees to transfer all of its right, title and
interest in and to the Patent Property to INNOVASC and MEDIFIX by means of an
assignment agreement, substantially in the form of the Assignment Agreement
attached hereto as Exhibit E.
14. Expenses. The reasonable legal fees and expenses of INNOVASC and
MEDIFIX, up to an aggregate amount of $5,000 in United States Dollars, incurred
in connection with the negotiation and preparation of this Agreement and the
transactions contemplated hereby shall be paid by KENSEY NASH upon the receipt
by KENSEY NASH of an invoice reasonably satisfactory to it.
14
<PAGE> 15
IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement under seal as if done so on the date first above written.
ATTEST: KENSEY NASH CORPORATION
(CORPORATE SEAL)
____________________________ By /s/ Joseph W. Kaufmann
---------------------------------
Joseph Kaufmann, President & CEO
ATTEST: INNOVASC R&D BV TE ROTTERDAM
(CORPORATE SEAL)
By: /s/ Wouter M. Muijs Van de Moer
- ---------------------------- --------------------------------
Its: Director
--------------------------------
ATTEST: MEDIFIX R&D BV TE PUTTEN
(CORPORATE SEAL)
By: /s/ Rienk Rienks
- ---------------------------- --------------------------------
Its: Director
--------------------------------
WITNESS: WOUTER M. MUIJS VAN DE MOER
(Print Name under signature)
/s/ Egbert Ottevanger /s/ Wouter M. Muijs Van de Moer
- ---------------------------- -------------------------------------
WITNESS: RIENK RIENKS
(Print Name under signature)
/s/ Egbert Ottevanger /s/ Rienk Rienks
- ---------------------------- ------------------------------------
15
<PAGE> 16
EXHIBIT A
ORIGINAL, PENDING AND GRANTED
PATENTS AND PATENT APPLICATIONS
OF WOUTER MUIJS VAN DE MOER AND RIENK RIENKS
<TABLE>
<CAPTION>
APPLICATION/PATENT
COUNTRY NO. DATE FILED STATUS
------- -------------------- ----------------- ---------------------
<S> <C> <C> <C>
Netherlands NL8901350 May 29, 1989 Abandoned
Netherlands PCT/NL90/00078 May 29, 1990 Expired
European Patent Appln. No. Patent EP 0474752
Convention (EPC) 90909191.0 May 29, 1990 Granted June 28, 1995
Austria
Belgium
Denmark
France
Germany
Great Britain
Italy
Luxembourg
Netherlands
Spain
Sweden
Switzerland
United States 07/776,281 November 21, 1991 Abandoned
United States 08/248,571 May 24, 1994 Abandoned
United States 08/369,264 January 5, 1995 Patent 5,620, 461
Granted April 15, 1997
United States 08/837,965 April 14, 1997 Pending
United States 07/781,091 October 22, 1991 Abandoned
</TABLE>
16
<PAGE> 17
<TABLE>
<CAPTION>
APPLICATION/PATENT
COUNTRY NO. DATE FILED STATUS
---------- -------------------- ----------------- --------------------
<S> <C> <C> <C>
United States 08/187,788 January 26, 1994 Abandoned
United States 08/369,588 January 6, 1995 Patent 5,593,422 Granted
January 14, 1997
United States 08/779,432 January 7, 1997 Pending
Canada Appln. No. 2,056,629 May 29, 1990 Patent 2,056,629 Granted
December 31, 1996
Japan 508684/90 May 29, 1990 Pending
Singapore 9791787 February 24, 1997 Pending
</TABLE>
17
<PAGE> 18
EXHIBIT D
ASSIGNMENT AGREEMENT
WHEREAS Wouter M. Muijs Van de Moer ("VAN DE MOER")and Rienk Rienks
("RIENKS"), both citizens of the Netherlands and residing at Grindweg 56, 3055
VB Rotterdam, Netherlands and Mennestraat 17, 3882 AN Putten, Netherlands,
respectively (hereinafter collectively referred to as "VAN DE MOER/RIENKS"),
have made inventions relating to the sealing of openings in blood vessels and
are the owners of various patent applications and patents relating thereto as
set forth in Exhibit A attached hereto (all of said inventions, issued patents,
pending patent applications and any and all patents, both United States and
foreign, issuing from said pending patent applications and/or any applications
based thereon being herein collectively referred to as "Patent Rights");
WHEREAS, VAN DE MOER on or about August 11, 1995 contributed and
transferred to INNOVASC R&D BV te Rotterdam (hereinafter referred to as
"INNOVASC") all of his right, title and interest in and to the Patent Rights,
and RIENKS on or about August 11, 1995 contributed and transferred to MEDIFIX
R&D BV te Putten (hereinafter referred to as "MEDIFIX") all of his right, title
and interest in and to the Patent Rights;
WHEREAS, INNOVASC and MEDIFIX are in the process of filing all required
notices of said assignments and transfers but have not made or completed all
such filings as of the date of this Assignment Agreement;
18
<PAGE> 19
WHEREAS, Kensey Nash Corporation (hereinafter referred to as "KENSEY
NASH") a corporation organized and existing under the laws of the State of
Delaware, having offices at 55 East Uwchlan Avenue, Exton, PA 19341, is
desirous of acquiring the entire right, title and interest in and to the Patent
Rights and in and to all divisional, continuing, renewal, reissue, or other
applications based upon the Patent Rights and any and all patents issuing from
any of said divisional, continuing, renewal, reissue, or other applications
based upon the Patent Rights.
NOW, THEREFORE, IN CONSIDERATION of the sum of One Dollar ($1.00), and
other good and valuable consideration, the receipt of which is hereby
acknowledged, the undersigned INNOVASC and MEDIFIX jointly and severally, by
these presents do sell, assign and transfer unto the said KENSEY NASH its
entire right, title and interest in and throughout the United States, its
territories and all countries foreign thereto in and to the Patent Rights, in
and to all divisionals, continuing, renewal, reissue, or other applications
based upon the Patent Rights, and any and all patents issuing from any of said
divisional, continuing, renewal, reissue, or other applications based upon the
Patent Rights.
TO BE HELD AND ENJOYED by said KENSEY NASH and its legal representatives
and assigns to the full ends of the terms for which said patents, or any of
them, have been granted as fully and entirely as the same would have been held
and enjoyed by us had no sale and assignment of said interest been made; and
the undersigned jointly and severally do hereby authorize and request the
Commissioner of Patents and Trademarks to issue any and all Letters Patent
which may be granted upon
19
<PAGE> 20
the said Patent Rights and/or upon all divisionals, continuing, renewal,
reissue, or other applications based upon the Patent Rights to KENSEY NASH; and
the undersigned hereby agree for the undersigned and the undersigned's
successors and assigns, to execute without further consideration, any further
legal documents and any further assignments and any releases, reissues,
renewals or other applications for Letters Patent that may be deemed necessary
by KENSEY NASH, fully to secure to KENSEY NASH its interest as aforesaid in and
to said Patent Rights or any part thereof, and all divisionals, continuing,
renewal, reissue, or other applications based upon the Patent Rights, and any
and all patents issuing from any of said divisional, continuing, renewal,
reissue, or other applications based upon the Patent Rights, or any of them.
The undersigned do hereby covenant jointly and severally for the
undersigned and the undersigned's legal representatives, and agree with KENSEY
NASH, and its legal representatives, as of date of the execution of this deed
that the undersigned then had good right and title in and to the Patent Rights
and that the undersigned have not executed and will not execute any instrument
in conflict therewith.
20
<PAGE> 21
IN WITNESS WHEREOF, the undersigned Innovasc R&D BV te Rotterdam, by our
duly authorized ________, Wouter M. Muijs Van de Moer, and Medifix R&D BV te
Putten, by our duly authorized ______ Rienk Rienks, execute this Assignment
Agreement this __ day of _________, 1997.
Innovasc R&D BV te Rotterdam
By
---------------------------------------
Wouter M. Muijs Van de Moer, Director
-------------
Medifix R&D BV te Putten
By
---------------------------------------
Rienk Rienks, Director
----------------------------
IN WITNESS WHEREOF, Kensey Nash Corporation, by its duly authorized
President, Joseph Kaufmann, executed this Agreement this ____ day of ________,
1997.
Kensey Nash Corporation
By
-------------------------------
Joseph Kaufmann, President and CEO
21
<PAGE> 22
EXHIBIT E
FORM OF ASSIGNMENT AGREEMENT
WHEREAS, on ______________________ INNOVASC R&D BV te Rotterdam
(hereinafter referred to as "INNOVASC") and MEDIFIX R&D BV te Putten
(hereinafter referred to as "MEDIFIX") assigned (said assignment being
hereinafter referred to as the "Prior Assignment") to KENSEY NASH CORPORATION,
a corporation organized and existing under the laws of the State of Delaware
and having offices at 55 East Uwchlan Avenue, Exton, PA 19341 (hereinafter
referred to as "KENSEY NASH"), all right, title and interest in and to certain
"Patent Rights" (the term "Patent Rights" being defined in said Prior
Assignment) in inventions relating to the sealing of openings in blood vessels,
to various patent applications and patents relating to such inventions, and in
and to all divisionals, continuing, renewal, reissue, or other applications
based upon the Patent Rights, and any and all patents issuing from any of said
divisional, continuing, renewal, reissue, or other applications based upon the
Patent Rights (all of the foregoing being hereinafter collectively referred to
as "Transferred Patent Rights"); and
WHEREAS, said Prior Assignment was recorded in the United States Patent
and Trademark Office on __________________ at Reel No. ______________, Frame
No. ________________, and a copy of which is attached hereto as Exhibit 1;
NOW THEREFORE, IN CONSIDERATION of the sum of One Dollar ($1.00), and
other good and valuable consideration, the receipt of which is hereby
acknowledged, KENSEY NASH by these presents does hereby resell, reassign and
retransfer unto the said INNOVASC and MEDIFIX,
22
<PAGE> 23
jointly and severally, KENSEY NASH'S entire right, title and interest in and
throughout the United States, its territories and all countries foreign thereto
in and to those Transferred Patent Rights which have been transferred to KENSEY
NASH by said Prior Assignment.
TO BE HELD AND ENJOYED by said INNOVASC and MEDIFIX and their legal
representatives and assigns to the full ends of the terms for which said
patents, or any of them, have been granted as fully and entirely as the same
would have been held and enjoyed by KENSEY NASH had no sale and assignment of
said interest been made; and KENSEY NASH does hereby authorize and request the
Commissioner of Patents and Trademarks to issue any and all Letters Patent
which may be granted upon those Transferred Patent Rights transferred to KENSEY
NASH by said Prior Assignment to INNOVASC and MEDIFIX, jointly and severally;
and KENSEY NASH agrees for itself, its successors and assigns, to execute
without further consideration, any further legal documents and any further
assignments and any releases, reissues, renewals or other applications for
Letters Patent that may be deemed necessary by INNOVASC and MEDIFIX, fully to
secure to INNOVASC and MEDIFIX their interest as aforesaid in and to those
Transferred Patent Rights transferred to KENSEY NASH by said Prior Assignment.
KENSEY NASH does hereby covenant for itself and its legal representatives,
and agrees with INNOVASC and MEDIFIX, and their legal representatives, as of
the date of the execution of this deed that KENSEY NASH then had good right and
title in and to those Transferred Patent Rights transferred to KENSEY NASH by
said Prior Assignment and that KENSEY NASH has not executed and will not
execute any instrument in conflict therewith.
23
<PAGE> 24
IN WITNESS WHEREOF, KENSEY NASH CORPORATION by its duly authorized _______
__________________________, has executed this Assignment Agreement on this ____
day of ___________, 199_.
24
<PAGE> 25
KENSEY NASH CORPORATION
By
---------------------------
-------------------------
IN WITNESS WHEREOF, INNOVASC R&D BV te Rotterdam, by Wouter M. Muijs Van
de Moer its duly authorized ______________________________, and MEDIFIX R&D BV
te Putten, by Rienk Rienks its duly authorized _____________________, have
executed this Assignment Agreement this ____ day of _________, 199_.
INNOVASC R&D BV the Rotterdam
By
----------------------------
Wouter M. Muijs Van de Moer
MEDIFIX R&D BV the Putten
By
----------------------------
Rienk Rienks
25
<PAGE> 26
SCHEDULE 1
----------
<TABLE>
<CAPTION>
PERCENTAGE OF
SHARES ISSUED AT CLOSING TIME PERIOD
------------------------------------------
<S> <C>
12.5% 3 MONTHS AFTER CLOSING
12.5% 6 MONTHS AFTER CLOSING
12.5% 9 MONTHS AFTER CLOSING
12.5% 12 MONTHS AFTER CLOSING
12.5% 15 MONTHS AFTER CLOSING
12.5% 18 MONTHS AFTER CLOSING
12.5% 21 MONTHS AFTER CLOSING
12.5% 24 MONTHS AFTER CLOSING
</TABLE>
26
